Search results for "1506"

showing 10 items of 235 documents

Educational needs in gastrointestinal cancer: a consensus position paper from the ESMO Gastrointestinal Cancer Faculty

2019

Gastrointestinal (GI) cancers are common in all parts of the world. Effective prevention and early detection of GI cancers are not universally implemented. Therefore, it must be anticipated that the incidence and the mortality of GI cancers will remain high within the next decades. The European Society for Medical Oncology (ESMO) Gastrointestinal Cancer Faculty aims to increase the skills of medical oncologists and other disciplines involved in treating GI malignancies. We aimed to increase the survival chances for patients with GI cancers, augment their quality of life and enable successful return to normal social and professional life during the period of survivorship. ESMO also aims to d…

Cancer Researchmedicine.medical_specialtygastrointestinal cancerDelphi methodEarly detectionReviewlcsh:RC254-282decision makingmultidisciplinarity03 medical and health sciences0302 clinical medicineQuality of life (healthcare)Survivorship curveparasitic diseasesMedicine030212 general & internal medicineGastrointestinal cancer1506educationbusiness.industryIncidence (epidemiology)social sciencesmedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens3. Good healthOncology030220 oncology & carcinogenesisFamily medicinePosition paperpopulation characteristicsclinical trainingbusinessGi cancerhuman activities
researchProduct

A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced o…

2019

Purpose This study investigated the safety and clinical activity of lumretuzumab, a humanised antihuman epidermal growth factor receptor 3 (HER3) monoclonal antibody, in combination with carboplatin and paclitaxel in first-line treatment of patients with squamous non-small cell lung cancer (sqNSCLC). HER3 ligand heregulin and HER3 protein expression were evaluated as potential biomarkers of clinical activity. Patients and methods This open-label, phase Ib/II study enrolled patients receiving lumretuzumab at 800 mg (flat) in combination with carboplatin (area under the curve (AUC) 6 mg/mL×min) and paclitaxel (200 mg/m 2) administered intravenously on a every 3-week schedule. Adverse event (A…

Cancer Researchnon-small cell lung cancer (NSCLC)phase ilcsh:RC254-282chemistry.chemical_compoundErbB3heregulinMedicineERBB3Epidermal growth factor receptor1506squamousOriginal Researchbiologybusiness.industryArea under the curveLumretuzumabmedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensCarboplatinnon-small cell lung cancer (NSCLC)OncologychemistryPaclitaxelhuman epidermal growth factor receptor 3 (HER3)Cancer researchbiology.proteinNeuregulinbiomarkerbusinessESMO open
researchProduct

Reproducible research practices, openness and transparency in health economic evaluations: study protocol for a cross-sectional comparative analysis

2020

INTRODUCTION: There has been a growing awareness of the need for rigorously and transparent reported health research, to ensure the reproducibility of studies by future researchers. Health economic evaluations, the comparative analysis of alternative interventions in terms of their costs and consequences, have been promoted as an important tool to inform decision-making. The objective of this study will be to investigate the extent to which articles of economic evaluations of healthcare interventions indexed in MEDLINE incorporate research practices that promote transparency, openness and reproducibility. METHODS AND ANALYSIS: This is the study protocol for a cross-sectional comparative ana…

Cost-Benefit Analysisdata sharingMEDLINEcost-effectiveness analysis data sharing methodology quality reporting reproducibility03 medical and health sciencesHealth Economics0302 clinical medicineHealth careProtocolOpenness to experienceHumansMedicine17011506030212 general & internal medicinereproducibilityProtocol (science)reportingMedical educationbusiness.industry030503 health policy & servicesCost-effectiveness analysiscost-effectiveness analysisRMethodologyReproducibility of ResultsmethodologyGeneral MedicineCost-effectiveness analysisTransparency (behavior)QualityReproducibility3. Good healthEconomics MedicalData sharingCross-Sectional StudiesReportingResearch DesignqualityEconomic evaluationMedicineData sharingQuality-Adjusted Life Years0305 other medical sciencebusiness
researchProduct

Counselling for physical activity, life-space mobility and falls prevention in old age (COSMOS): protocol of a randomised controlled trial.

2019

IntroductionThe most promising way to promote active life years in old age is to promote regular participation in physical activity (PA). Maintaining lower extremity muscle function with good balance has been associated with fewer falls and the need of help from others. This article describes the design and intervention of a randomised controlled trial (RCT) investigating the effectiveness of a health and PA counselling programme on life-space mobility and falls rates in community-dwelling older adults at the Health Kiosk and/or Service Centre.Methods and analysisCommunity-dwelling men and women (n=450) aged 65 years and over with early phase mobility limitation will be recruited to a 24-mo…

CounselingMalephysical activityFear of fallinglaw.inventionolder people0302 clinical medicineRandomized controlled triallawActivities of Daily LivingPreventive Health ServicesfallsProtocolMedicine030212 general & internal medicine1506Postural BalanceRandomized Controlled Trials as TopickaatuminenSisätaudit - Internal medicineCognitionGeneral Medicine3. Good healthcounsellingFemaleIndependent LivingPublic Healthmedicine.symptomikääntyneetfyysinen aktiivisuusmedicine.medical_specialtylife-space mobilityterveyden edistäminen03 medical and health sciencesterveysneuvontaQuality of life (healthcare)Intervention (counseling)liikuntakykyHumans1724Mobility LimitationExerciseBalance (ability)AgedProtocol (science)business.industryResistance TrainingMoodPhysical therapyQuality of LifeAccidental Fallsbusiness030217 neurology & neurosurgeryProgram EvaluationBMJ open
researchProduct

Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia

2021

BackgroundT-cell acute lymphoblastic leukemia (T-ALL) is an aggressive disease with a poor cure rate for relapsed/resistant patients. Due to the lack of T-cell restricted targetable antigens, effective immune-therapeutics are not presently available and the treatment of chemo-refractory T-ALL is still an unmet clinical need. To develop novel immune-therapy for T-ALL, we generated an afucosylated monoclonal antibody (mAb) (ahuUMG1) and two different bispecific T-cell engagers (BTCEs) against UMG1, a unique CD43-epitope highly and selectively expressed by T-ALL cells from pediatric and adult patients.MethodsUMG1 expression was assessed by immunohistochemistry (IHC) on a wide panel of normal t…

Cytotoxicity ImmunologicCancer Research2434T-LymphocytesMice SCIDafucosylated monoclonal antibodyLymphocyte ActivationPrecursor T-Cell Lymphoblastic Leukemia-LymphomaEpitopesJurkat CellsAntineoplastic Agents ImmunologicalAntibody SpecificityMice Inbred NODantigensAntibodies BispecificTumor MicroenvironmentImmunology and Allergyantibodieshematologic neoplasms1506RC254-282Antibody-dependent cell-mediated cytotoxicityLeukosialinbispecific T-cell engagersmedicine.diagnostic_testbiologyhematological malignancieNeoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.anatomical_structureantibodieOncologytranslational medical researchMolecular MedicineImmunohistochemistryFemaleimmunotherapyAntibodyT-ALLT-cell engagersT-cell acute lymphoblastic leukemiamedicine.drug_classT cellImmunologySettore MED/08 - Anatomia PatologicaMonoclonal antibodyAntibodies Monoclonal HumanizedFlow cytometryT Acute Lymphoblastic LeukemiaantigenAntigenPhagocytosismedicineAnimalsHumanshematological malignanciesCell ProliferationPharmacologyT-cell engagerbusiness.industryhematological malignancies; antibodies; antigens; hematologic neoplasms; immunotherapy; neoplasm; T-ALL; T-cell engagers; translational medical research; translational researchBasic Tumor ImmunologyXenograft Model Antitumor Assaystranslational researchCancer researchbiology.proteinneoplasmbusinesshematologic neoplasmneoplasm
researchProduct

Preventive strategies and factors associated with surgically treated necrotising enterocolitis in extremely preterm infants: an international unit su…

2019

ObjectivesTo compare necrotising enterocolitis (NEC) prevention practices and NEC associated factors between units from eight countries of the International Network for Evaluation of Outcomes of Neonates, and to assess their association with surgical NEC rates.DesignProspective unit-level survey combined with retrospective cohort study.SettingNeonatal intensive care units in Australia/New Zealand, Canada, Finland, Israel, Spain, Sweden, Switzerland and Tuscany (Italy).PatientsExtremely preterm infants born between 240to 286weeks’ gestation, with birth weights<1500 g, and admitted between 2014–2015.ExposuresNEC prevention practices (probiotics, feeding, donor milk) using responses of an o…

Data AnalysisMalePediatricsInternationalityDatabases FactualInfant Premature Diseases2700 General Medicinepaediatric gastroenterologyCohort Studiesperinatology0302 clinical medicineRisk FactorsCause of DeathSurveys and QuestionnairesHospital Mortality1506030212 general & internal medicineOriginal ResearchIncidence (epidemiology)General MedicinePrognosis3. Good healthPrimary PreventionTreatment OutcomeInfant Extremely PrematureCohortGestationFemale1719Cohort studymedicine.medical_specialty610 Medicine & healthneonatologySepsis03 medical and health sciencesEnterocolitis NecrotizingIntensive Care Units Neonatal030225 pediatricsIntensive caremedicineHumansNeonatologyRetrospective Studiesbusiness.industryProbioticsInfant NewbornPaediatricsRetrospective cohort studymedicine.disease10027 Clinic for NeonatologySurvival Analysisdigestive system diseasesbusiness
researchProduct

Protocol of a multicenter international randomized controlled manikin study on different protocols of cardiopulmonary resuscitation for laypeople (MA…

2018

IntroductionOut-of-hospital cardiac arrest is one of the leading causes of death in industrialised countries. Survival depends on prompt identification of cardiac arrest and on the quality and timing of cardiopulmonary resuscitation (CPR) and defibrillation. For laypeople, there has been a growing interest on hands-only CPR, meaning continuous chest compression without interruption to perform ventilations. It has been demonstrated that intentional interruptions in hands-only CPR can increase its quality. The aim of this randomised trial is to compare three CPR protocols performed with different intentional interruptions with hands-only CPR.Methods and analysisThis is a prospective randomise…

Defibrillationmedicine.medical_treatmenteducation030204 cardiovascular system & hematologyManikinscardiopulmonary resuscitationcardiopulmonary resuscitation; feedback devices; training; Medicine (all)03 medical and health sciencesContinuous chest compression0302 clinical medicineInformed consentProtocolmedicineHumans1506Prospective StudiesCardiopulmonary resuscitationTrial registrationRandomized Controlled Trials as TopicProtocol (science)trainingbusiness.industryMedicine (all)Ethics committeeBasic life support030208 emergency & critical care medicineGeneral Medicinemedicine.disease1691feedback deviceItalyfeedback devicesEmergency MedicineMedical emergencybusinessOut-of-Hospital Cardiac Arrest
researchProduct

Congenital secretory diarrhoea caused by activating germline mutations in GUCY2C

2016

Objective Congenital sodium diarrhoea (CSD) refers to a form of secretory diarrhoea with intrauterine onset and high faecal losses of sodium without congenital malformations. The molecular basis for CSD remains unknown. We clinically characterised a cohort of infants with CSD and set out to identify disease-causing mutations by genome-wide genetic testing. Design We performed whole-exome sequencing and chromosomal microarray analyses in 4 unrelated patients, followed by confirmatory Sanger sequencing of the likely disease-causing mutations in patients and in their family members, followed by functional studies. Results We identified novel de novo missense mutations in GUCY2C, the gene encod…

DiarrheaMale0301 basic medicinemedicine.medical_specialtyReceptors PeptideColonGuanylinGuanosine MonophosphateMutation MissenseReceptors EnterotoxinGUANYLATE CYCLASEBiologyCHRONIC DIARRHOEAPathogenesis03 medical and health scienceschemistry.chemical_compoundsymbols.namesakeGermline mutationInternal medicineBACTERIAL ENTEROTOXINSmedicineHumansMissense mutationAbnormalities MultipleGenetic Predisposition to Disease1506Intestinal MucosaCyclic guanosine monophosphateSanger sequencingPAEDIATRIC DIARRHOEASodiumGastroenterologyInfantMolecular Reproduction Development & Genetics (formed by the merger of DBGL and CRBME)Molecular biologyIntestines030104 developmental biologyEndocrinologyIntestinal AbsorptionReceptors Guanylate Cyclase-CoupledchemistryINTESTINAL ION TRANSPORTsymbolsFemaleMetabolism Inborn ErrorsIntracellularUroguanylinGut
researchProduct

Predicting the risk of drug–drug interactions in psychiatric hospitals: a retrospective longitudinal pharmacovigilance study

2021

ObjectivesThe aim was to use routine data available at a patient’s admission to the hospital to predict polypharmacy and drug–drug interactions (DDI) and to evaluate the prediction performance with regard to its usefulness to support the efficient management of benefits and risks of drug prescriptions.DesignRetrospective, longitudinal study.SettingWe used data from a large multicentred pharmacovigilance project carried out in eight psychiatric hospitals in Hesse, Germany.ParticipantsInpatient episodes consecutively discharged between 1 October 2017 and 30 September 2018 (year 1) or 1 January 2019 and 31 December 2019 (year 2).Outcome measuresThe proportion of rightly classified hospital epi…

DrugHospitals PsychiatricLongitudinal studymedicine.medical_specialtymedia_common.quotation_subjectHealth informaticslaw.invention03 medical and health sciencesPharmacovigilance0302 clinical medicinelawRisk FactorsGermanyPharmacovigilanceMedicineHumans1723Drug Interactions030212 general & internal medicine1506Longitudinal StudiesMedical prescriptionPsychiatryhealth informaticsmedia_commonRetrospective StudiesPolypharmacyClinical pharmacologyReceiver operating characteristicbusiness.industryRGeneral MedicinePharmacology and Therapeuticspsychiatry030227 psychiatryPharmaceutical PreparationsMedicineclinical pharmacologybusinessBMJ Open
researchProduct

Global injury morbidity and mortality from 1990 to 2017 : results from the Global Burden of Disease Study 2017

2020

Publisher's version (útgefin grein)

DánarmeinFötlunDánartíðniLífslíkurLife expectancy1106 Human Movement and Sports Sciencesburden of diseaseGlobal HealthGlobal Burden of Disease0302 clinical medicineQuality-Adjusted Life YearGlobal healthMedicineLIFE EXPECTANCY030212 general & internal medicine1506POPULATIONCause of deathOriginal ResearchRISKeducation.field_of_studyGlobal disease burdensInjuriesSjúkdómarIncidence (epidemiology)IncidencePopulation healthBurden of diseaseGlobalglobal3142 Public health care science environmental and occupational health3. Good healthDescriptive epidemiologyLýðheilsaQuality-Adjusted Life YearsPublic HealthTERRITORIESdescriptive epidemiologyHumanPopulation195 COUNTRIESPopulation healthCause of deathburden of disease; descriptive epidemiology; global; Humans; Incidence; Life Expectancy; Morbidity; Quality-Adjusted Life Years; Global Burden of Disease; Global Health; Wounds and Injuries1117 Public Health and Health Services03 medical and health sciencesAGESYSTEMATIC ANALYSISHumansMortalityeducationDisabilitySEX-SPECIFIC MORTALITYbusiness.industryFaraldsfræðiDISABILITYPublic Health Environmental and Occupational HealthQuality-adjusted life yearYears of potential life lostÁverkar1701 PsychologyLife expectancyWounds and InjuriesHuman medicineMorbiditybusiness030217 neurology & neurosurgeryDemography
researchProduct